mofezolac has been researched along with Chronic Disease in 1 studies
mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Satoh, K | 1 |
| Furukawa, H | 1 |
| Nasu, Y | 1 |
| Sone, H | 1 |
| Ichiki, T | 1 |
| Kodama, R | 1 |
| Kuwata, M | 1 |
| Yamashita, K | 1 |
1 other study available for mofezolac and Chronic Disease
| Article | Year |
|---|---|
[Fifty two-week chronic oral toxicity study of mofezolac (N-22) in rats].
Topics: Administration, Oral; Anemia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Fem | 1990 |